<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497939</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2005.310-T</org_study_id>
    <secondary_id>HARECCTR0500050</secondary_id>
    <nct_id>NCT00497939</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Saw Palmetto and Sanmiaoshan on Benign Prostatic Hyperplasia in Chinese Patients</brief_title>
  <official_title>The Effectiveness of Saw Palmetto and Sanmiaoshan on International Prostate Symptom Score and Peak Urinary Flow Rate of Chinese Patients With Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of saw palmetto and sanmiaoshan, on top of
      alpha blocker, on urinary flow rate and BPH symptoms in patients with BPH.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in IPSS between the study medication and placebo groups</measure>
    <time_frame>At study enrolment, after six month of study medication or placebo administration, at the end of washout period and after six month of alternative drug treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in Qmax between the study medication and placebo groups</measure>
    <time_frame>At study enrolment, after six month of study medication or placebo administration, at the end of washout period and after six month of alternative drug treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in IPSS and Qmax at baseline and at the end of treatment drug / placebo treatment</measure>
    <time_frame>From study enrolment/ after washout period to the end of study medication / placebo administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean urinary flow rate, post-void residual volume, prostate volume, PSA and GHQ score between study medication group and placebo group</measure>
    <time_frame>At study enrolment, after six month of study medication or placebo administration, at the end of washout period and after six month of alternative drug treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean urinary flow rate, post-void residual volume, prostate volume, PSA and GHQ score between study medication group and baseline, and placebo group and baseline</measure>
    <time_frame>From study enrolment/ after washout period to the end of study medication / placebo administration</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <condition>Adrenergic Alpha-Antagonists</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saw palmetto and sanmiaoshan capsule</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 50 and 80 years old

          -  Clinically diagnosed to have BPH:

               -  Suffered from lower urinary tract symptoms with IPSS&gt;=8

               -  Detectable prostatic enlargement determined by DRE

               -  Urinary flow between 5 and 15ml/second in a total void volume &gt;=150mL

               -  Serum PSA level less than 4ng/ml or in between 4-10 ng/ml with percent free PSA
                  &gt;25% or&gt;=4 with cancer excluded by biopsy

        Exclusion Criteria:

          -  Acute retention of urine

          -  Congestive heart failure, unstable angina, arrhythmia, myocardial infraction

          -  Prostatic surgery

          -  Prostatic malignancy

          -  Gastrointestinal disease

          -  Renal impairment with serum creatinine &gt;140 umol/l

          -  Hepatic disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Chi Fai Ng, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Division of Urology, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annie YF Wong, Miss</last_name>
    <phone>(852) 2632 2501</phone>
    <email>anniewong@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ping Chung Leung, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ekg.org.hk/HAREC-CTR/RegistryDisplay2.jsp?HARECID=HARECCTR0500050</url>
    <description>HAREC Clinical Trial Registry</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2007</study_first_submitted>
  <study_first_submitted_qc>July 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2007</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <keyword>Benign Prostatic Hyperplasia (BPH)</keyword>
  <keyword>Currently on alpha blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saw palmetto extract</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

